Drug Approval | July 03, 2022
Pfizer submits new drug application to the U.S. FDA for Paxlovid
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies
First and only PARP inhibitor to improve invasive disease-free survival in patients
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
It´s the first trial to demonstrate the benefits of dual pathway inhibition
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.
Subscribe To Our Newsletter & Stay Updated
